Levomilnacipran

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 119 publications

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis.

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis.

Journal: BMJ open
Published: October 08, 2025

Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system.

Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system.

Journal: Frontiers in pharmacology
Published: October 07, 2025

Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range.

Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range.

Journal: The Journal of clinical psychiatry
Published: August 28, 2025

Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies.

Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: June 29, 2025

Nickel-catalyzed highly diastereo- and enantioselective hydroaminocarbonylation and hydrocarboxylation of cyclopropenes.

Nickel-catalyzed highly diastereo- and enantioselective hydroaminocarbonylation and hydrocarboxylation of cyclopropenes.

Journal: Nature communications
Published: May 28, 2025

Factors associated with initial medication adherence with first-line therapy for depression.

Factors associated with initial medication adherence with first-line therapy for depression.

Journal: Journal of affective disorders
Published: May 11, 2025

Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.

Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.

Journal: JAMA psychiatry
Published: April 02, 2025

Optimization of Levomilnacipran Loaded Nanostructured Lipid Carrier Using Response Surface Methodology.

Optimization of Levomilnacipran Loaded Nanostructured Lipid Carrier Using Response Surface Methodology.

Journal: Pharmaceutical nanotechnology
Published: February 27, 2025

CD9, a novel potential biomarker of sarcopenia.

CD9, a novel potential biomarker of sarcopenia.

Journal: Scientific reports
Published: February 25, 2025

The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.

The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.

Journal: Lancet (London, England)
Published: February 19, 2025

Repurposing levomilnacipran to attenuate premature ovarian insufficiency induced by cyclophosphamide in female Wistar albino rats through modulation of TLR4/p38-MAPK/NF-κB p65, caspase-3-driven apoptosis, and Klotho protein expression.

Repurposing levomilnacipran to attenuate premature ovarian insufficiency induced by cyclophosphamide in female Wistar albino rats through modulation of TLR4/p38-MAPK/NF-κB p65, caspase-3-driven apoptosis, and Klotho protein expression.

Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
Published: January 17, 2025

Gastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study.

Gastrointestinal adverse events associated with SNRIs: A FAERS-based pharmacovigilance study.

Journal: Journal of affective disorders
Published: December 31, 2024
Showing 1-12 of 119

Last Updated: 02/24/2026